重组人源化抗白介素-6受体单克隆抗体对类风湿关节炎临床疗效及骨代谢的影响  

Effect of Recombinant Humanized Anti IL-6R Monoclonal Antibody on Clinical Efficacy and Bone Metabolism in Rheumatoid Arthritis

作　　者：葛洪亮 谢洁 柳毓文 胡建康[1] GE Hongliang;XIE Jie;LIU Yuwen;HU Jiankang(Pingxiang People's Hospital,Jiangxi Province,Pingxiang 337000,China;不详)

机构地区：[1]江西省萍乡市人民医院,江西萍乡337000 [2]江西省萍乡市第三人民医院

出　　处：《中国医学创新》2023年第26期19-23,共5页Medical Innovation of China

基　　金：萍乡市科技计划培育类项目(2019PY025)。

摘　　要：目的:探讨重组人源化抗白介素-6受体单克隆抗体对类风湿关节炎(RA)临床疗效及骨代谢的影响。方法:选取2019年8月—2022年3月于萍乡市人民医院就诊并确诊RA患者60例,按随机数字表法将患者分为治疗组和对照组,各30例。治疗组采用重组人源化抗白介素-6受体单克隆抗体+甲氨蝶呤+稳定剂量泼尼松治疗,对照组采用甲氨蝶呤+稳定剂量泼尼松治疗。于治疗前和治疗3、6个月检测两组患者机体的C反应蛋白、类风湿因子、血沉、骨钙素(OC)、骨密度,评估两组患者的视觉模拟评分法(VAS)评分、Sharp评分及安全性。结果:两组治疗3、6个月的C反应蛋白、类风湿因子、血沉、VAS评分均明显低于治疗前(P<0.05),且治疗组治疗3、6个月上述指标均明显低于对照组(P<0.05)。两组治疗3、6个月的OC均高于治疗前(P<0.05),且治疗组治疗3、6个月OC均高于对照组(P<0.05);两组治疗前后股骨颈骨密度组间和组内比较,差异均无统计学意义(P>0.05)。两组治疗3、6个月的Sharp评分均低于治疗前(P<0.05),且治疗组治疗3、6个月的Sharp评分均低于对照组(P<0.05)。治疗组不良事件发生率虽高于对照组,但两组比较差异无统计学意义(P>0.05)。结论:重组人源化抗白介素-6受体单克隆抗体可有效降低RA患者的C反应蛋白、类风湿因子及血沉水平,缓解其疼痛,升高OC,降低Sharp评分,且不会增加不良事件的发生,安全性较高。Objective:To investigate the effect of Recombinant Humanized Anti IL-6R Monoclonal Antibody on the clinical efficacy and bone metabolism in rheumatoid arthritis(RA).Method:A total of 60 patients diagnosed with RA in Pingxiang People's Hospital from August 2019 to March 2022 were selected and divided into treatment group and control group according to random number table method,with 30 patients in each group.The treatment group was treated with Recombinant Humanized Anti IL-6R Monoclonal Antibody+Methotrexate+stable dose Prednisone,while the control group was treated with Methotrexate+stable dose Prednisone.The C reactive protein,rheumatoid factor,erythrocyte sediment,osteocalcin(OC)and bone mineral density of the two groups were detected before treatment and 3 and 6 months after treatment,visual analogue scale(VAS)score,Sharp score and safety of the two groups were evaluated.Result:After 3 and 6 months of treatment,the C reactive protein,rheumatoid factor,erythrocyte sedimentation rate and VAS scores in two groups were significantly lower than those before treatment(P<0.05),and the above indexes in the treatment group were significantly lower than those in the control group(P<0.05).The OC of 3 and 6 months after treatment in both groups were higher than those before treatment(P<0.05),and the OC of 3 and 6 months after treatment in the treatment group were higher than those of control group(P<0.05).There were no significant differences in femoral neck bone mineral density before and after treatment between the two groups and within two groups(P>0.05).Sharp scores of 3 and 6 months after treatment in the two groups were lower than those before treatment(P<0.05),and Sharp scores of 3 and 6 months after treatment in the treatment group were lower than those in the control group(P<0.05).The incidence of adverse events in the treatment group was higher than that in the control group,but there was no significant difference between the two groups(P>0.05).Conclusion:Recombinant Humanized Anti IL-6R Monoclonal Antibody can

关 键 词：重组人源化抗白介素-6受体单克隆抗体 类风湿关节炎 骨代谢 

分 类 号：R593.22[医药卫生—内科学]